Gilead Sciences, Inc. $GILD Stake Lifted by AMF Tjanstepension AB

AMF Tjanstepension AB lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.3% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 542,262 shares of the biopharmaceutical company’s stock after acquiring an additional 17,302 shares during the period. AMF Tjanstepension AB’s holdings in Gilead Sciences were worth $75,575,000 as of its most recent filing with the SEC.

Several other large investors have also recently added to or reduced their stakes in GILD. Strategic Investment Solutions Inc. IL bought a new position in Gilead Sciences in the 4th quarter valued at about $25,000. Vermillion & White Wealth Management Group LLC grew its position in Gilead Sciences by 71.4% during the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 85 shares in the last quarter. Quattro Advisors LLC acquired a new stake in Gilead Sciences during the 4th quarter worth about $26,000. Wealth Preservation Advisors LLC boosted its position in Gilead Sciences by 60.0% during the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 81 shares during the last quarter. Finally, Ares Financial Consulting LLC acquired a new stake in Gilead Sciences in the fourth quarter valued at approximately $28,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Gilead Sciences

In other news, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction on Friday, May 15th. The shares were sold at an average price of $131.29, for a total transaction of $3,676,120.00. Following the completion of the transaction, the insider directly owned 125,779 shares in the company, valued at approximately $16,513,524.91. This represents a 18.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $131.46, for a total value of $1,971,900.00. Following the sale, the chief executive officer owned 617,567 shares in the company, valued at approximately $81,185,357.82. This trade represents a 2.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 83,000 shares of company stock valued at $10,824,500 in the last ninety days. 0.30% of the stock is currently owned by company insiders.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $129.83 on Monday. Gilead Sciences, Inc. has a 1 year low of $107.75 and a 1 year high of $157.29. The firm has a market capitalization of $161.19 billion, a P/E ratio of 17.69 and a beta of 0.32. The firm’s fifty day moving average price is $129.78 and its two-hundred day moving average price is $135.03. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.91 by $0.12. The business had revenue of $6.96 billion during the quarter, compared to the consensus estimate of $6.91 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The company’s quarterly revenue was up 4.4% on a year-over-year basis. During the same quarter last year, the firm posted $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, research analysts anticipate that Gilead Sciences, Inc. will post -0.8 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, June 29th. Investors of record on Monday, June 15th were given a dividend of $0.82 per share. The ex-dividend date of this dividend was Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.5%. Gilead Sciences’s dividend payout ratio is currently 44.69%.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on GILD shares. Leerink Partners lowered their price target on Gilead Sciences from $148.00 to $146.00 in a report on Friday, May 8th. Morgan Stanley dropped their price target on shares of Gilead Sciences from $168.00 to $166.00 and set an “overweight” rating for the company in a research report on Wednesday, July 8th. The Goldman Sachs Group raised their price objective on shares of Gilead Sciences from $125.00 to $130.00 and gave the stock a “neutral” rating in a report on Friday, April 17th. Cantor Fitzgerald restated an “overweight” rating and issued a $155.00 price objective on shares of Gilead Sciences in a research report on Monday, July 6th. Finally, Daiwa Securities Group reduced their price target on shares of Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 19th. Twenty-six research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and a consensus price target of $159.04.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.